NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
05/22/2026
Back to search
Official data from USPTO
(STAQ PHARMA) SAFETY | TRANSPARENCY | AVAILABILITY | QUALITY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
05/23/2026
Trademark type
Combined
Nice classes
40
Filing date
10/14/2019
Registration date
12/29/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/22/2026
Last transaction
05/23/2026
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
04/02/2020
First use in commerce
07/10/2020
Drawing code
3
Owner type
03
Owner location
Denver, CO, US
Examiner
MARCY, AMY ALFIERI
Current location
Historical data usage
Mark description
The mark consists of the word "STAQ PHARMA" in blue font with yellow, purple and green squares between the letters, all inside black parenthesis, with the word "SAFETY" in green font, the word "TRANSPARENCY" in yellow font, the word "AVAILABILITY" in blue font, and the word "QUALITY" in purple font with black vertical lines between words.
Holders and representatives
Holders
STAQ Pharma, Inc.
Representatives
Abram Gordon
Technical classification
Nice Classes
Class 40
Vienna Codes
No Vienna codes available.
Goods and services
Class 40
Custom manufacture of pharmaceuticals by pharmaceutical compounders
Publications
History of USPTO decisions and trademark events.
28 publications found
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
05/22/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/18/2026
E815
TEAS SECTION 8 & 15 RECEIVED
02/26/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
12/29/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
12/29/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/24/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/21/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/10/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/10/2020
IUAF
USE AMENDMENT FILED
10/27/2020
EISU
TEAS STATEMENT OF USE RECEIVED
10/27/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/12/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/17/2020
PUBO
PUBLISHED FOR OPPOSITION
03/17/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/26/2020
ALIE
ASSIGNED TO LIE
02/10/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/01/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/31/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/31/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/29/2020
GNRT
NON-FINAL ACTION E-MAILED
01/29/2020
CNRT
NON-FINAL ACTION WRITTEN
01/29/2020
DOCK
ASSIGNED TO EXAMINER
01/18/2020
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/19/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/18/2019
NWAP
NEW APPLICATION ENTERED
10/17/2019
Continuous trademark protection
Get notified about every new filing that threatens (STAQ PHARMA) SAFETY | TRANSPARENCY | AVAILABILITY | QUALITY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.